Table 4.
Correlation between immunohistochemical expression of BAF250a (ARID1A), mismatch repair proteins, and p53 within the entire cohort and within the endometrioid and serous subtypes
|
BAF250a+
|
BAF250a
–
|
||||
|---|---|---|---|---|---|
| n | % | n | % | P | |
| Entire cohort | |||||
| MMR intact | 108 | 85% | 19 | 15% | <0.0001 |
| MMR lost | 27 | 43% | 36 | 57% | |
| p53 normal | 52 | 50% | 52 | 50% | <0.0001 |
| p53 aberrant | 83 | 96% | 3 | 4% | |
| Endometrioid carcinomas | |||||
| MMR intact | 24 | 69% | 11 | 31% | 0.026 |
| MMR lost | 20 | 42% | 27 | 58% | |
| p53 normal | 31 | 46% | 36 | 54% | 0.0083 |
| p53 aberrant | 13 | 87% | 2 | 13% | |
| Serous carcinomas | |||||
| MMR intact | 75 | 95% | 4 | 5% | 0.0031 |
| MMR lost | 5 | 56% | 4 | 44% | |
| p53 normal | 13 | 65% | 7 | 35% | <0.0001 |
| p53 aberrant | 67 | 98% | 1 | 2% | |